Compare SOTK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | MAIA |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 79.0M |
| IPO Year | 1995 | 2022 |
| Metric | SOTK | MAIA |
|---|---|---|
| Price | $4.73 | $1.35 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.5K | ★ 569.7K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 33.33 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $94.40 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.40 | $0.87 |
| 52 Week High | $6.24 | $3.19 |
| Indicator | SOTK | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 50.62 |
| Support Level | $3.81 | $1.25 |
| Resistance Level | $4.75 | $1.48 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 49.21 | 44.74 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.